Identification and application of plant-derived cytochrome P450
By identifying and using the cytochrome P450 enzymes MtCYP108 and MtCYP150 to construct engineered bacteria, the problems of resource waste and environmental pollution in the production of C21 steroid substances were solved, and an efficient biosynthesis pathway was achieved.
Patent Information
- Application Number
- CN202310637551.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the production of C21 steroid substances has problems with waste of land resources and environmental pollution, and the enzyme activity in the biosynthetic pathway is low, which limits the development of the de novo synthesis route.
The cytochrome P450 enzymes MtCYP108 and MtCYP150 that can catalyze the synthesis of prenatalinol and cholesterol were identified from the Tongshiji vine, and the biosynthesis of prenatalinol was achieved through its encoding gene construction.
It provides high-active enzymes for the biosynthesis of C21 steroid drugs, reduces dependence on land resources and environmental pollution, and improves the efficiency of biosynthesis pathways.
Smart Images

Figure CN119060968A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to newly identified plant-derived cytochrome P450 polypeptides and their use in the production of steroidal compounds. Background Art
[0002] C21 steroids (e.g., pregnenolone, progesterone, hydrocortisone, etc.) are an important class of compounds that have been shown to have significant physiological effects in animals, such as endocrine regulation, anti-inflammatory, and anti-tumor effects. At present, there are two main industrial routes for the production of C21 steroids: the diene method and the 4-AD method. However, the basic raw materials of the diene method and the 4-AD method are mainly compounds such as diosgenin and stigmasterol obtained by plant extraction and separation. On the one hand, the production of these compounds wastes a lot of land resources, and the residues left after extraction and separation are very harmful to the environment. On the other hand, some steroid compounds need to be derived by chemical synthesis, and this process requires a large amount of toxic and harmful reagents and has poor sustainability. Therefore, constructing a microbial cell factory to synthesize C21 steroid compounds from scratch using glucose as a substrate has the advantages of economic savings and environmental friendliness, and its potential as the third route for the development of synthetic biology methods is worth looking forward to. Efficient analysis of biosynthetic pathways is a prerequisite for synthetic biology production. Scientists have identified the biosynthetic pathways of C21 compounds such as pregnenolone and progesterone in animals, but the low activity of the enzymes has restricted the development of the entire de novo synthesis route based on cheap carbon sources such as glucose.
[0003] Earlier scientists detected C21 steroid compounds in plants, with an abundance as high as 12% of dry cell weight, but their biosynthetic pathway and the catalytic activity of the pathway were unknown.
[0004] Therefore, there is a need to identify highly active enzymes involved in the biosynthetic pathway of C21 compounds, such as enzymes of plant origin. Summary of the invention
[0005] To meet the above needs, the inventors discovered the key enzymes MtCYP108 and MtCYP150 (identified as cytochrome P450) in the plant Marsdenia tenacissima, which can catalyze the synthesis of pregnenolone from campesterol and cholesterol, and constructed an engineered bacterium capable of producing pregnenolone using their encoding genes, providing an important basis for the de novo biosynthesis of C21 steroid drugs.
[0006] In a first aspect, the present invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or 14.
[0007] In a second aspect, the present invention provides an isolated polynucleotide encoding a polypeptide of the present invention or a vector comprising the polynucleotide.
[0008] In a third aspect, the present invention provides a recombinant host cell, preferably a yeast cell, such as a Saccharomyces cerevisiae cell, comprising a polynucleotide or a vector of the present invention.
[0009] In some embodiments, the polynucleotide is integrated into the genome of the host cell.
[0010] In some embodiments, the host cell further comprises a polynucleotide encoding a protein associated with cholesterol and / or campesterol biosynthesis.
[0011] In some embodiments, the cholesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, protein disulfide isomerase, INO2 protein; cytochrome P450 reductase, 7-dehydrocholesterol reductase and sterol 24-position reductase; and / or wherein the campesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, cytochrome P450 reductase, 7-dehydrocholesterol reductase.
[0012] In some embodiments, the host cell lacks a galactokinase gene, such as one or more of the GAL1, GAL7, and GAL10 genes.
[0013] In a fourth aspect, the present invention provides a polypeptide-membrane complex comprising the polypeptide of the present invention and a membrane comprising a lipid bilayer.
[0014] In a fifth aspect, the present invention provides a method for preparing pregnenolone, comprising contacting the host cell or the complex of the present invention with cholesterol and / or campesterol.
[0015] In some embodiments, the method for preparing pregnenolone of the present invention comprises culturing the host cell of the present invention under conditions suitable for its growth, wherein the host cell further comprises a polynucleotide encoding a protein related to cholesterol and / or campesterol biosynthesis. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1It shows that the cytochrome P450 polypeptide of the present invention can catalyze the reaction of converting cholesterol into pregnenolone. A is the GC-MS analysis peak diagram of pregnenolone and cholesterol standards, wherein peaks 1 and 2 are pregnenolone and cholesterol respectively; B, C, and D are the GC-MS analysis peak diagrams of the fermentation products of strains CHOL-Mt150, CHOL-Mt108, and CHOL02 respectively; E and G represent the mass spectra of peaks 1 and 2 in the fermentation products of strains CHOL02, CHOL-Mt150, and CHOL-Mt108 respectively; F and H are the mass spectra of pregnenolone and cholesterol respectively; I is the biosynthetic pathway of cholesterol synthesizing pregnenolone in plants.
[0017] Figure 2 The cytochrome P450 polypeptide of the present invention can catalyze the reaction of converting campesterol into pregnenolone. A is the GC-MS analysis peak diagram of pregnenolone and campesterol standards, wherein peaks 1 and 2 are pregnenolone and campesterol, respectively; B, C, and D are the GC-MS analysis peak diagrams of the fermentation products of strains CAOL-Mt150, CAOL-Mt108, and CAOL01, respectively; E and G represent the mass spectra of peaks 1 and 2 in the fermentation products of strains CAOL-Mt150, CAOL-Mt108, and CAOL01, respectively; F and H are the mass spectra of pregnenolone and campesterol, respectively; and I is the biosynthetic pathway of campesterol to synthesize pregnenolone in plants. DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention provides a plant-derived cytochrome P450 polypeptide, a polynucleotide encoding or encoding the polypeptide, a vector or a host cell, a complex comprising the polypeptide and a membrane (comprising a lipid bilayer), and a method for preparing pregnenolone using the polypeptide, the host cell or the complex. Unless otherwise specified, the terms used herein have the meanings generally understood by those skilled in the art.
[0020] The prior art reports enzymes of animal origin that participate in the biosynthesis pathway of C21 compounds. However, the low activity of the enzymes limits the development of synthetic biology (de novo synthesis) of C21 compounds.
[0021] 1. Cytochrome P450 Peptides
[0022] The inventors identified the key enzymes MtCYP108 and MtCYP150 (SEQ ID NOs: 13 and 14) from Rhizoma Atractylodis Macrocephalae that can catalyze the synthesis of pregnenolone from campesterol or cholesterol, which were identified as cytochrome P450 (see Figure 1 I and Figure 2 I).
[0023] Therefore, the present invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or 14.
[0024] As used herein, the term "peptide" refers to a chain of at least two amino acids linked by peptide bonds. The term "polypeptide" is used interchangeably with the term "protein" herein to refer to a chain containing ten or more amino acid residues. All peptide and polypeptide formulas or sequences herein are written from left to right, indicating the direction from the amino terminus to the carboxyl terminus.
[0025] The term "amino acid" includes naturally occurring amino acids and non-natural amino acids in proteins. The single-letter and three-letter nomenclature of naturally occurring amino acids in proteins adopts the common names in the art, which can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual, 2nd, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
[0026]
[0027] The present invention also encompasses modified forms of the polypeptide, ie, amino acid sequences comprising variants of SEQ ID NO: 13 or 14.
[0028] As used herein, the term "modification" refers to any modification of a polypeptide consisting of the polypeptide of the present invention or a homologous sequence thereof, including but not limited to, substitution, deletion, insertion and / or addition of one or more amino acids.
[0029] As used herein, the term "variant" refers to a polypeptide or nucleic acid that has a certain sequence identity compared to the amino acid or nucleotide sequence of a given polypeptide or nucleic acid.
[0030] In the present invention, "variant" encompasses naturally occurring variants. In some embodiments, the polypeptide is a polypeptide naturally occurring in Thunbergia lappa.
[0031] For the present invention, to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for the purpose of optimal comparison (e.g., gaps may be introduced in the first amino acid or nucleic acid sequence for optimal alignment with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, the molecules are identical at this position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., percent identity = number of identical positions / total number of positions (i.e., overlapping positions) × 100). Preferably, the two sequences are of the same length.
[0032] Those skilled in the art are aware that various computer programs can be used to determine the identity between two sequences.
[0033] "Percent amino acid identity" or "percent amino acid sequence identity" refers to comparing the amino acids of two polypeptides, when optimally aligned, the two polypeptides have about a specified percentage of identical amino acids. For example, "95% amino acid identity" means comparing the amino acids of two polypeptides, when optimally aligned, the two polypeptides have 95% of the same amino acids.
[0034] In some embodiments, the polypeptide comprises an amino acid sequence having at least 65% or 70%, preferably at least 75% or 80%, more preferably at least 85% or 90%, particularly preferably at least 94%, 95%, 96%, 97%, 98% or 99%, most preferably at least 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with an amino acid sequence selected from SEQ ID NO: 13 or 14, and the polypeptide has a catalytic Figure 1 I and / or Figure 2 I. In some embodiments, the polypeptide is a polypeptide naturally present in Thunbergia lappa.
[0035] In some embodiments, the amino acid sequence of the polypeptide differs from the amino acid sequence selected from SEQ ID NO: 13 or 14 in that one or more amino acids are substituted, deleted, inserted and / or added, and the polypeptide has a catalytic Figure 1 I and / or Figure 2 I reaction activity. In some embodiments, the amino acid sequence of the polypeptide has one or more conservative substitutions of amino acids compared to the amino acid sequence selected from SEQ ID NO: 13 or 14, and the polypeptide has a catalytic Figure 1 I and / or Figure 2I reaction activity. In some embodiments, the amino acid sequence of the polypeptide has one or more amino acid insertions or deletions compared to the amino acid sequence selected from SEQ ID NO: 13 or 14, and the polypeptide has a catalytic Figure 1 I and / or Figure 2 I. In some embodiments, the polypeptide is a polypeptide naturally present in Thunbergia lappa.
[0036] The term "conservative substitution", also known as substitution by a "homologous" amino acid residue, refers to substitutions in which the amino acid residue is replaced by an amino acid residue having a similar side chain, for example, amino acids with basic side chains (e.g., lysine, arginine and histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), non-charged polar side chain amino acids (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chain amino acids (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chain amino acids (e.g., threonine, valine, isoleucine) and aromatic side chain amino acids (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0037] Conservative amino acid substitutions generally have the least effect on the activity of the resulting protein. Such substitutions are described below. Conservative substitutions are replacements of an amino acid with an amino acid that is similar in size, hydrophobicity, charge, polarity, steric characteristics, aromaticity, etc. Such substitutions are generally conservative when it is desired to fine-tune the properties of a protein.
[0038] As used herein, "homologous" amino acid residues refer to amino acid residues with similar chemical properties, such as hydrophobicity, charge, polarity, steric characteristics, aromatic characteristics, etc. Examples of amino acids homologous to each other include positively charged lysine, arginine, histidine, negatively charged glutamic acid, aspartic acid, hydrophobic glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, polar serine, threonine, cysteine, methionine, tryptophan, tyrosine, asparagine, glutamine, aromatic phenylalanine, tyrosine, tryptophan, serine and threonine with chemically similar side chain groups, or glutamine and asparagine, or leucine and isoleucine.
[0039] Examples of conservative substitutions of amino acids in proteins include: Ser for Ala, Lys for Arg, Gln or His for Asn, Glu for Asp, Ser for Cys, Asn for Gln, Asp for Glu, Pro for Gly, Asn or Gln for His, Leu or Val for Ile, Ile or Val for Leu, Arg or Gln for Lys, Leu or Ile for Met, Met, Leu or Tyr for Phe, Thr for Ser, Ser for Thr, Tyr for Trp, Trp or Phe for Tyr, and Ile or Leu for Val.
[0040] 2. Polynucleotides and Vectors
[0041] The present invention provides polynucleotides encoding the polypeptides of the present invention.
[0042] As used herein, the term "polynucleotide" generally refers to a nucleic acid molecule (e.g., 100 bases up to 30 kilobases in length) and a sequence that is complementary (antisense) or identical (sense) to a sequence of a messenger RNA (mRNA) or mRNA fragment or molecule. The term may also refer to a transcribed or non-transcribed DNA or RNA molecule.
[0043] As used herein, the term "coding" refers to a polynucleotide that directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by an open reading frame, which usually begins with the ATG start codon or other start codons such as GTG and TTG and ends with stop codons such as TAA, TAG and TGA. The coding sequence can be a DNA, cDNA or recombinant nucleotide sequence.
[0044] In some embodiments, the polynucleotide of the present invention comprises a nucleotide sequence encoding SEQ ID NO:13 or 14, for example, the nucleotide sequence at positions 669-2105 of SEQ ID NO:11 or the nucleotide sequence at positions 669-2087 of SEQ ID NO:12.
[0045] As used herein, similar to polypeptides, a polynucleotide has a certain percentage of "sequence identity" with another polynucleotide, which means the percentage of bases that are identical when aligned. Sequence identity can be determined in many different ways. To determine sequence identity, methods and computer programs including BLAST (ncbi.nlm.nih.gov / BLAST / ) can be used to align sequences. Another alignment algorithm is FASTA, available from Genetics Computing Group (GCG), (Madison, Wisconsin, USA).
[0046] In some embodiments, the polynucleotide of the present invention comprises a nucleotide sequence having at least 65% or 70%, preferably at least 75% or 80%, more preferably at least 85% or 90%, particularly preferably at least 94%, 95%, 96%, 97%, 98% or 99%, and most preferably at least 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with the nucleotide sequence of positions 669-2105 of SEQ ID NO: 11 or the nucleotide sequence of positions 669-2087 of SEQ ID NO: 12, and the polypeptide encoded by the polynucleotide has a catalytic effect. Figure 1 I and / or Figure 2 I. In some embodiments, the polynucleotide encodes a polypeptide naturally present in Thunbergia lappa.
[0047] Furthermore, nucleic acid molecules encompassing all or part of the nucleic acid sequences of the present invention can be isolated by polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based on the sequence information contained in the sequences.
[0048] The polynucleotides of the present invention can be amplified using cDNA, mRNA or genomic DNA as templates and suitable oligonucleotide primers according to standard PCR amplification techniques. The nucleic acids amplified in this way can be cloned into suitable vectors and characterized by DNA sequence analysis.
[0049] The polynucleotides of the present invention can be prepared by standard synthetic techniques, for example, using an automated DNA synthesizer.
[0050] The present invention also relates to complementary strands of the nucleic acid molecules described herein.A nucleic acid molecule that is complementary to another nucleotide sequence is a molecule that is sufficiently complementary to that nucleotide sequence such that it can hybridize to the other nucleotide sequence to form a stable duplex.
[0051] As used herein, the term "hybridization" means that nucleotide sequences at least about 90%, preferably at least about 95%, more preferably at least about 96%, and more preferably at least 98% homologous to each other typically remain hybridized to each other under given stringent hybridization and washing conditions.
[0052] Those skilled in the art are aware of various conditions for hybridization, such as stringent hybridization conditions and highly stringent hybridization conditions. See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, John Wiley & Sons, NY.
[0053] Of course, the polynucleotide of the present invention does not include a polynucleotide that hybridizes only to a poly A sequence (such as the 3' terminal poly (A) of mRNA) or to a complementary stretch of poly T (or U) residues.
[0054] 3. Expression of the polypeptide
[0055] To express the modified polypeptides of the present invention, polynucleotide constructs and vectors, such as expression vectors, comprising the polynucleotides of the present invention are also provided.
[0056] As used herein, the term "polynucleotide construct" refers to a single-stranded or double-stranded polynucleotide that is isolated from a naturally occurring gene or modified to include a non-naturally occurring nucleic acid fragment. When a polynucleotide construct includes control sequences required for expressing a coding sequence of the present invention, the polynucleotide construct includes an "expression cassette."
[0057] As used herein, the term "expression cassette" refers to a polynucleotide segment comprising a polynucleotide encoding a polypeptide operably linked to additional nucleotide sequences that provide for the expression of the polynucleotide, such as control sequences.
[0058] As used herein, the term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0059] The term "expression vector" herein refers to a linear or circular DNA molecule comprising a polynucleotide encoding a polypeptide of the present invention, the polynucleotide being operably linked to additional nucleotides, e.g., control sequences, that provide for the expression of the polynucleotide. The expression vector includes a viral vector or a plasmid vector.
[0060] "Control sequences" include all elements necessary or beneficial for the expression of a polynucleotide encoding a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleotide sequence encoding the polypeptide, or native or foreign to each other. Such control sequences include, but are not limited to, a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, an enhancer, a signal peptide sequence, and a transcription terminator. A control sequence includes at least a promoter and a signal to terminate transcription and translation.
[0061] For example, the control sequence can be a suitable promoter sequence, which is recognized by the host cell to express the nucleotide sequence of the polynucleotide encoding the polypeptide. The promoter sequence comprises a transcription control sequence that mediates the expression of the polypeptide. The promoter can be any nucleotide sequence that exhibits transcriptional activity in the selected host cell, such as the lac operon of Escherichia coli. The promoter also includes mutant, truncated and hybrid promoters, and can be obtained from genes encoding extracellular or intracellular polypeptides that are homologous or heterologous to the host cell.
[0062] As used herein, the term "operably linked" refers to the configuration of a control sequence at an appropriate position relative to the coding sequence of a polynucleotide sequence, wherein the control sequence directs the expression of the polypeptide coding sequence.
[0063] In some embodiments, the polynucleotide construct of the present invention comprises a promoter and / or terminator operably linked to the polynucleotide of the present invention. For example, the promoter may comprise a nucleotide sequence at positions 1-668 of SEQ ID NO: 11; and / or the terminator may comprise a nucleotide sequence at positions 2106-2355 of SEQ ID NO: 11. In some embodiments, the polynucleotide construct of the present invention comprises a nucleotide sequence of SEQ ID NO: 11 or 12.
[0064] The polynucleotide encoding the polypeptide of the present invention may be subjected to various manipulations to allow the polypeptide to be expressed. Manipulation of the polynucleotide may be desirable or necessary depending on the expression vector prior to its insertion into the vector. Techniques for modifying polynucleotide sequences using recombinant DNA methods are well known in the art.
[0065] In order to identify and select host cells comprising expression vectors of the present invention, vectors of the present invention preferably contain one or more selectable markers, which allow simple selection of cells for transformation, transfection, transduction, etc. A selectable marker is a gene whose product provides biocide or virus resistance, heavy metal resistance, supplementary auxotrophy, etc. For example, the selectable marker of bacteria is the dal gene from Bacillus subtilis or Bacillus licheniformis, or a marker that confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. For yeast, for example, amino acid auxotrophy markers can be used, such as selected from histidine (HIS3), leucine (LEU2), uracil (URA3), tryptophan (TRP1) auxotrophy markers, or antibiotic resistance such as hygromycin, geneticin (G418).
[0066] The vector of the present invention can be integrated into the host cell genome or replicate autonomously in the cell independently of the genome. The elements required for integration into the host cell genome or autonomous replication are known in the art (see, for example, Sambrook et al., 1989, supra).
[0067] Vector DNA can be introduced into prokaryotic or eukaryotic cells by conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" refer to various techniques recognized in the art for introducing exogenous nucleic acid (e.g., DNA) into host cells, as found in, for example, the aforementioned Sambrook et al., 1989; Davis et al., Basic Methods in Molecular Biology (1986) and other laboratory manuals.
[0068] The present invention also relates to a recombinant host cell comprising a polynucleotide of the present invention, which is advantageously used in the recombinant expression of a polypeptide of the present invention. A vector comprising a polynucleotide of the present invention is introduced into a host cell, whereby the vector is retained as a chromosomal integrant or as a self-replicating extrachromosomal vector. Conventional vectors and host cells for expressing proteins are known to those skilled in the art.
[0069] The host cell of the present invention can be a prokaryotic cell or a eukaryotic cell. The prokaryotic cell includes, but is not limited to, a bacterial (such as Escherichia coli (E. coli)) cell, an actinomycete cell, a cyanobacterial cell, and an archaeal cell. The eukaryotic cell includes, but is not limited to, a fungal (such as a filamentous fungus or yeast) cell, a plant cell, an animal cell, and an algae (such as a microalgae) cell.
[0070] In some embodiments, the host cell of the present invention is a yeast cell, including but not limited to Saccharomyces cerevisiae, Yarrowia lipolytica, Schizosaccharomyces pombe, Pichia pastoris and Candida. In some embodiments, the polynucleotide construct expressing the polypeptide of the present invention is integrated into the yeast chromosome. In some embodiments, the host cell also comprises a polynucleotide encoding a protein related to cholesterol and / or campesterol biosynthesis. In some embodiments, the polynucleotide encoding a protein related to cholesterol and / or campesterol biosynthesis is integrated into the yeast chromosome.
[0071] In some embodiments, the cholesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, protein disulfide isomerase, INO2 protein; cytochrome P450 reductase, 7-dehydrocholesterol reductase and sterol 24-position reductase; and / or wherein the campesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, cytochrome P450 reductase, 7-dehydrocholesterol reductase.
[0072] In some embodiments, the cholesterol biosynthesis-related protein is at least one selected from the group consisting of the protein encoded by positions 676-2259 of SEQ ID NO:1, the protein encoded by positions 608-2164 of SEQ ID NO:2, the protein encoded by positions 676-1977 of SEQ ID NO:3, the protein encoded by positions 751-2334 of SEQ ID NO:4, the protein encoded by positions 801-1715 of SEQ ID NO:5, the protein encoded by positions 431-1999 of SEQ ID NO:6, the protein encoded by positions 669-2219 of SEQ ID NO:7, the protein encoded by positions 601-2715 of SEQ ID NO:8, and the protein encoded by positions 669-1973 of SEQ ID NO:9, and preferably all of them.
[0073] In some embodiments, the protein related to campesterol biosynthesis is at least one selected from the group consisting of the protein encoded by positions 676-2259 of SEQ ID NO: 1, the protein encoded by positions 608-2164 of SEQ ID NO: 2, the protein encoded by positions 676-1977 of SEQ ID NO: 3, the protein encoded by positions 669-1973 of SEQ ID NO: 9, and the protein encoded by positions 669-2783 of SEQ ID NO: 10, preferably all of them.
[0074] In some embodiments, the host cell comprises an expression cassette for expressing a protein related to cholesterol and / or campesterol biosynthesis. In some embodiments, the expression cassette for expressing a protein related to cholesterol biosynthesis comprises at least one, preferably all, of the nucleotide sequences selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, and 9. In some embodiments, the expression cassette for expressing a protein related to campesterol biosynthesis comprises at least one, preferably all, of the nucleotide sequences selected from SEQ ID NOs: 1, 2, 3, 9, and 10.
[0075] In some embodiments, the host cell lacks a galactokinase gene, such as one or more of the GAL1, GAL7, and GAL10 genes.
[0076] 4. Peptide-Membrane Complex
[0077] The present invention provides a polypeptide-membrane complex comprising the polypeptide of the present invention and a membrane comprising a lipid bilayer.
[0078] 5. Method for preparing pregnenolone
[0079] The present invention provides a method for preparing pregnenolone, comprising contacting the host cell or the complex of the present invention with cholesterol and / or campesterol.
[0080] In some embodiments, the method for preparing pregnenolone of the present invention comprises the following steps:
[0081] (a) providing a host cell or a complex of the present invention to a reaction medium comprising cholesterol and / or campesterol, and
[0082] (b) incubating the reaction medium to produce pregnenolone.
[0083] In some embodiments, the incubation is carried out at 20-50°C, preferably 25-40°C, more preferably 28-35°C, such as 30°C.
[0084] In some embodiments, practicing the method further comprises providing oxygen to the reaction medium.
[0085] In some embodiments, the medium is culture medium used to culture the host cells.
[0086] The present invention also provides a method for preparing pregnenolone, comprising culturing the host cell of the present invention under conditions suitable for its growth, wherein the host cell further comprises a polynucleotide encoding a protein related to cholesterol and / or campesterol biosynthesis. In some embodiments, the polynucleotide encoding a protein related to cholesterol and / or campesterol biosynthesis is integrated into a yeast chromosome.
[0087] In some embodiments, the cholesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, protein disulfide isomerase, INO2 protein; cytochrome P450 reductase, 7-dehydrocholesterol reductase and sterol 24-position reductase; and / or wherein the campesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, cytochrome P450 reductase, 7-dehydrocholesterol reductase.
[0088] In some embodiments, the cholesterol biosynthesis-related protein is at least one selected from the group consisting of the protein encoded by positions 676-2259 of SEQ ID NO:1, the protein encoded by positions 608-2164 of SEQ ID NO:2, the protein encoded by positions 676-1977 of SEQ ID NO:3, the protein encoded by positions 751-2334 of SEQ ID NO:4, the protein encoded by positions 801-1715 of SEQ ID NO:5, the protein encoded by positions 431-1999 of SEQ ID NO:6, the protein encoded by positions 669-2219 of SEQ ID NO:7, the protein encoded by positions 601-2715 of SEQ ID NO:8, and the protein encoded by positions 669-1973 of SEQ ID NO:9, and preferably all of them.
[0089] In some embodiments, the protein related to campesterol biosynthesis is at least one selected from the group consisting of the protein encoded by positions 676-2259 of SEQ ID NO: 1, the protein encoded by positions 608-2164 of SEQ ID NO: 2, the protein encoded by positions 676-1977 of SEQ ID NO: 3, the protein encoded by positions 669-1973 of SEQ ID NO: 9, and the protein encoded by positions 669-2783 of SEQ ID NO: 10, preferably all of them.
[0090] In some embodiments, the host cell comprises an expression cassette for expressing a protein related to cholesterol and / or campesterol biosynthesis. In some embodiments, the expression cassette for expressing a protein related to cholesterol biosynthesis comprises at least one, preferably all, of the nucleotide sequences selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, and 9. In some embodiments, the expression cassette for expressing a protein related to campesterol biosynthesis comprises at least one, preferably all, of the nucleotide sequences selected from SEQ ID NOs: 1, 2, 3, 9, and 10.
[0091] In some embodiments, the host cell lacks a galactokinase gene, such as one or more of the GAL1, GAL7, and GAL10 genes. Example
[0092] The present invention will be further described in detail below in conjunction with specific examples. It should be noted that the following examples are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0093] The experimental methods in the following examples, unless otherwise specified, are all conventional methods in the art and can be performed according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0094] Unless otherwise specified, the nucleotide sequences in the examples are in the order from 5' to 3', and the amino acid sequences are in the order from N- to C-terminus.
[0095] SPSS11.5 statistical software was used to process the data. The experimental results were expressed as mean ± standard deviation and tested by One-way ANOVA.
[0096] The culture medium and composition used in the following examples are as follows (the yeast selection medium SD-Trp and SD-Trp-ura were purchased from Beijing Fanjinuo Technology Co., Ltd.):
[0097] SD-Trp solid selection medium: 0.8% yeast selection medium SD-Trp, 2% glucose, 2% agar powder;
[0098] SD-Trp liquid selection medium: 0.8% yeast selection medium SD-Trp, 2% glucose;
[0099] SD-Trp-Ura solid selection medium: 0.8% yeast selection medium SD-Trp-Ura, 2% glucose, 2% agar powder;
[0100] SD-Trp-Ura liquid selection medium: 0.8% yeast selection medium SD-Trp-Ura, 2% glucose;
[0101] SD-Trp-5FOA solid selection medium: 0.8% yeast selection medium SD-Trp, 2% glucose, 0.05% 5-FOA, 2% agar powder;
[0102] SD-Trp-Ura galactose induction liquid selection medium: 0.8% yeast selection medium SD-Trp-Ura, 1% galactose, 2% ethanol.
[0103] The nucleotide sequences and structures of the expression cassettes involved in the following examples are shown in Table 1.
[0104] Table 1. Expression cassettes for yeast modification
[0105]
[0106]
[0107] Example 1, plasmid construction
[0108] The purpose of this example is to construct a recombinant plasmid for engineering yeast.
[0109] 1. Cloning of coding sequences
[0110] 1. Cloning of nucleotide sequences encoding MtCYP108 and MtCYP150
[0111] Beijing Novogene Biotechnology Co., Ltd. was commissioned to extract RNA and sequence transcriptomes from the leaves, fruits and roots of Marsdenia tenacissima plants. The sequencing results were de novo spliced using the short reads assembly software Trinity. The open reading frame (ORF) sequences of MtCYP108 and MtCYP150 were determined by transcriptome data analysis, homology analysis and annotation, and the MtCYP108 and MtCYP150 genes were obtained based on the Pfam annotation of P450. PCR amplification was performed using specific primers with Marsdenia tenacissima cDNA as a template to obtain the nucleotide sequences encoding MtCYP108 and MtCYP150 (669-2105 of SEQ ID NO: 12 and 669-2087 of SEQ ID NO: 13).
[0112]
[0113]
[0114] The amplification system (50 μl in total) contains: HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0115] Amplification conditions included:
[0116] Pre-denaturation at 98°C for 3 minutes;
[0117] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0118] Extend at 72°C for 10 minutes.
[0119] 2. Cloning of Promoter and Terminator Elements
[0120] Use the Kangwei Century Yeast Genome Extraction Kit (Cat. No.: CW0569) to extract the genomic DNA of Saccharomyces cerevisiae strain YSBYT5 (see Shi, Y., et al. Engineering yeast subcellular compartments for increased production of the lipophilic natural products ginsenosides[J]. Metabolic engineering, 2021, 67:104-111) according to the manufacturer's instructions.
[0121] Using the genomic DNA of strain YSBYT5 as a template, the primers in Table 2 were used to amplify promoter GAL1p, promoter GAL7p and promoter GAL10p (see Table 2), respectively; using the genomic DNA of Saccharomyces cerevisiae YSBYT5 as a template, the primers in Table 2 were used to amplify terminator PRM9t, terminator SPG5t, terminator CWP2t (see Table 2) and GAL1-7-10 gene knockout upstream and downstream fragments, respectively, and then fusion PCR was performed according to the primer combination in Table 1 to obtain the GAL1-7-10 gene knockout fragment (SEQID NO: 98); and the PCR product was recovered.
[0122] The amplification system (50 μl in total) contains: HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0123] Amplification conditions included:
[0124] Pre-denaturation at 98°C for 3 minutes;
[0125] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, extension at 72°C for 3 minutes (30 cycles); and extension at 72°C for 10 minutes.
[0126] Table 2. Primers used for amplification
[0127]
[0128]
[0129] 3. Construction of recombinant plasmid
[0130] 1. Construction of pEASY-GAL1p-tHMG1-PRM9t, pEASY-GAL7p-cHMG2-SPG5t, and pEASY-GAL10p-HMGR-CWP2t plasmids
[0131] According to Table 3, the plasmid was used as a PCR template (pM2-tHMG1 and pM7-HMGR plasmids refer to: Li R, Wang K, Wang D, et al. Production of plant volatile terpenoids (rose oil) by yeast cell factories [J]. Green Chemistry, 2021, 23 (14)), PCR amplification was performed with the corresponding primers to obtain functional fragments respectively, and the PCR products were recovered.
[0132] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0133] Amplification conditions included:
[0134] Pre-denaturation at 98°C for 3 minutes;
[0135] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0136] Extend at 72°C for 10 minutes.
[0137] Table 3
[0138]
[0139]
[0140] The amplified products GAL1p-tHMG1-PRM9t, GAL7p-cHMG2-SPG5t, and GAL10p-HMGR-CWP2t were cloned into the pEASY-Blunt Simple cloning vector and transformed into Trans1-T1 competent cells using the All-Gold pEASY-Blunt Simple transformation kit. The plasmids were extracted and sequenced for verification to obtain plasmids pEASY-GAL1p-tHMG1-PRM9t, pEASY-GAL7p-cHMG2-SPG5t, and pEASY-GAL10p-HMGR-CWP2t.
[0141] 2. Construction of pM4-INO2, pEASY-GAL1p-GgDHCR24-PRM9t, pEASY-GAL1p-VvCPR-PRM9t, pEASY-GAL1p-MtCYP108-PRM9t, pEASY-GAL1p-MtCYP150-PRM9t, pEASY-GAL7p-VvCPR-SPG5t, and pEASY-GAL10p-StDWF5-CWP2t plasmids
[0142] According to the description in Table 4, the plasmid was used as a PCR template (for pM2-StDWF5, pM4-VvCPR, and pM3-GgDHCR24 plasmids, please refer to Xu, L, et al, Metabolic engineering of Saccharomyces cerevisiae for gram-scale diosgenin production[J]. Metabolic Engineering, 2022, 70:115-128) and PCR amplification was performed with primers to obtain each fragment, and the PCR products were recovered.
[0143] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0144] Amplification conditions included:
[0145] Pre-denaturation at 98°C for 3 minutes;
[0146] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, extension at 72°C for 3 minutes (30 cycles); and extension at 72°C for 10 minutes.
[0147] Table 4
[0148]
[0149]
[0150] The amplified pGAL1-ZT fragment, pGAL7-ZT fragment, pGAL10-ZT fragment, and pM4-ZT fragment PCR products were treated with Dpn1 enzyme for three hours, and the pGAL1-ZT fragment was connected with the Sc-GAL1p-VvCPR gene fragment, Sc-GgDHCR24 gene fragment, Sc-MtCYP108 gene fragment, and Sc-MtCYP150 gene fragment using a seamless cloning kit (purchased from Bio-Tech). The pGAL7-ZT fragment was connected with the Sc-GAL7p-VvCPR gene fragment; the pGAL10-ZT fragment was connected with the Sc-StDWF5 gene fragment; the pM4-ZT fragment was connected with the Sc-TDH3-INO2 gene fragment; and 5-10 μl was transferred into Trans1 T1 competent cells were cultured and sequenced to obtain plasmids pM4-INO2, pEASY-GAL1p-GgDHCR24-PRM9t, pEASY-GAL1p-VvCRP-PRM9t, pEASY-GAL1p-MtCYP108-PRM9t, pEASY-GAL1p-MtCYP150-PRM9t, pEASY-GAL7p-VvCRP-SPG5t, and pEASY-GAL10p-StDWF5-CWP2t.
[0151] 3. Construction of Ho-gRNA and GAL1p-gRNA plasmids
[0152] Using plasmid YPL062w-gRNA (see Shi, Y., et al. Engineering yeast subcellular compartments for increased production of the lipophilic natural products ginsenosides [J]. Metabolic engineering, 2021, 67: 104-111) as a template, the primers in Table 5 were used to amplify Ho-gRNA and GAL1p-gRNA fragments, respectively, and the PCR products were recovered.
[0153] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0154] Amplification conditions included:
[0155] Pre-denaturation at 98°C for 3 minutes;
[0156] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0157] Extend at 72°C for 10 minutes.
[0158] Table 5
[0159]
[0160]
[0161] The amplified Ho-gRNA and GAL1p-gRNA PCR products were treated with Dpn1 enzyme overnight using the pEASY-Blunt Simple transformation kit. Then 5-10 μl was transferred into Trans1 T1 competent cells and sequenced to obtain Ho-gRNA and GAL1p-gRNA plasmids.
[0162] The relevant information of the recombinant plasmid prepared above is shown in Table 6.
[0163] Table 6. Recombinant plasmids
[0164]
[0165] Example 2: Construction of recombinant strains
[0166] The purpose of this example is to construct a recombinant yeast strain that produces pregnenolone.
[0167] 2.1. Construction of CHOL02
[0168] According to Table 7, the plasmid was used as a PCR template and the corresponding primers were used for PCR amplification to obtain the functional expression cassettes and recover the PCR products. Fragment TEF1-PDI1-CYC1t see Li W, Ma X, Li G, et al. De Novo Biosynthesis of the Oleanane-Type Triterpenoids of Tunicosaponins in Yeast [J]. ACS Synthetic Biology, 2021; plasmid pM2-tHMG1 see Li R, Wang K, Wang D, et al. Production of plant volatile terpenoids (rose oil) by yeast cell factories [J]. Green Chemistry, 2021, 23 (14)
[0169] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0170] Amplification conditions included:
[0171] Pre-denaturation at 98°C for 3 minutes;
[0172] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0173] Extend at 72°C for 10 minutes.
[0174] Table 7
[0175]
[0176]
[0177] Strain CHOL02 was constructed from strain YSBYT5 using fragments M1-M9. Strain YSBYT5 contains the recombinant plasmid p414-PTEF1-Cas9-TCYC1 that can express the Cas9 protein. After the recombinant plasmid expressing gRNA and the recombinant fragments are transferred, the complex of the expressed gRNA and Cas9 recognizes the target site and introduces double-stranded DNA breaks. Then the recombinant fragments (M1-M9) containing the homologous regions are integrated into the genomic DNA of the strain through homologous recombination repair.
[0178] Specifically, the yeast chassis cell YSBYT5 was activated in SD-Trp liquid medium, and competent cells were prepared by the lithium acetate method. 2 μl of GAl1p-gRNA and 2 μl of GAL1-7-10-KO fragment were added to the competent cells, and the transformants were cultured in a 30°C incubator in SD-Trp-Ura solid selection medium for 48 hours and then streaked. The colonies were verified using primers GAL7-1-10-KO-OUT-F: CTCTGGATTTGGTGACATACAGTTC (SEQ ID NO: 81) and GAL7-1-10-KO-OUT-R: CCGGTCTAGGAAATCGGTGAAAG (SEQ ID NO: 82) (the PCR system and conditions were as described above). After verification, the gRNA plasmid in the cells was eliminated by culturing on SD-Trp-5FOA solid selection medium for 24 hours, and the resulting strain was named BY-RS01.
[0179] The strain BY-RS01 was activated in SD-Trp liquid selection medium, and competent cells were prepared by the lithium acetate method. 2 μl of plasmid YPL062W-gRNA (see Shi, Y., et al. Engineering yeast subcellular compartments for increased production of the lipophilic natural products ginsenosides [J]. Metabolic engineering, 2021, 67: 104-111) was added to the competent cells, and then the three module fragments M1, M2 and M3 obtained by the above amplification (total amount 3 μl) were added to the yeast competent cells at a molar ratio of 1:1:1. The transformants were cultured in SD-Trp-Ura solid selection medium at 30°C in an incubator for 48 hours and then streaked and verified by PCR using primers tHMG1-F: TCGTCGCAGAAGCTACTATTCCTG (SEQ ID NO: 83) and YPL062-OUT-R: TTAAACACGCCAGGCTTGACCT (SEQ ID NO: 84) (PCR system and conditions are as described above). After verification, the cells were cultured in SD-Trp-5FOA solid selection medium for 24 hours to eliminate the gRNA plasmid in the cells, and the resulting strain was named BY-RS02.
[0180] The strain BY-RS02 was activated in SD-Trp liquid selection medium, and competent cells were prepared by the lithium acetate method. 2 μl of plasmid ATF2-gRNA (see Xu, L, et al, Metabolic engineering of Saccharomyces cerevisiae for gram-scale diosgenin production [J]. Metabolic Engineering, 2022, 70: 115-128) was added to the competent cells, and then the three module fragments M4, M5 and M6 obtained by the above amplification (total amount of 3 μl) were added to the yeast competent cells at a molar ratio of 1:1:1. The transformants were cultured in SD-Trp-Ura solid selection medium at 30°C in an incubator for 48 hours and then streaked and verified by PCR using primers GgDHCR24-F: ACGAACCAGTTAGAGG TTTGAGATC (SEQ ID NO: 85) and ATF2-OUT-R: ATGCATCGACTACG AGCGTATTG (SEQ ID NO: 86) (PCR system and conditions are as described above). After verification, the cells were cultured in SD-Trp-5FOA solid selection medium for 24 hours to eliminate the gRNA plasmid in the cells, and the resulting strain was named CHOL01.
[0181] The strain CHOL01 was activated in SD-Trp liquid selection medium, and competent cells were prepared by the lithium acetate method. 2 μl of Ho-gRNA plasmid was added to the competent cells, and the three module fragments M7, M8 and M9 (total amount 3 μl) obtained by the above amplification were added to the yeast competent cells at a molar ratio of 1:1:1. The transformants were cultured in a 30°C incubator in SD-Trp-Ura solid selection medium for 48 hours and then streaked. The primers PDI1-F: ATGAACTTTGTTAGCATCGATGC (SEQ ID NO: 87) and Ho-OUT-R: CGCGTAAATATTTAGCTTGATAACTGTTACTG (SEQ ID NO: 88) were used for PCR verification (PCR system and conditions are as described above). After verification, the gRNA plasmid in the cells was eliminated by culturing in SD-Trp-5FOA solid selection medium for 24 hours, and the resulting strain was named CHOL02.
[0182] 2.2. Construction of the chassis strain CAOL01
[0183] According to Table 8, the plasmid was used as a PCR template and PCR amplification was performed with corresponding primers to obtain functional expression cassettes, and the PCR products were recovered.
[0184] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0185] Amplification conditions included:
[0186] Pre-denaturation at 98°C for 3 minutes;
[0187] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0188] Extend at 72°C for 10 minutes.
[0189] Table 8
[0190]
[0191] The strain BY-RS02 was activated in SD-Trp liquid selection medium, and competent cells were prepared by the lithium acetate method. 2 μl of plasmid ATF2-gRNA was added to the competent cells, and the two module fragments M10 and M11 (total amount 2 μl) obtained by the above amplification were added to the yeast competent cells at a molar ratio of 1:1. The transformants were cultured in SD-Trp-Ura solid selection medium at 30°C incubator for 48 hours and streaked, and PCR verification was performed using primers VvCPR-F: ATGAATACGCTCAATGGGTTGTCG (SEQ ID NO: 90) and ATF2-OUT-R: ATGCATCGACTACGAGCGTATTG (SEQ ID NO: 91) (PCR system and conditions are as described above). After verification, the gRNA plasmid in the cells was eliminated by culturing in SD-Trp-5FOA solid selection medium for 24 hours, and the resulting strain was named CAOL01.
[0192] 2.3. Construction of recombinant strain producing pregnenolone
[0193] PCR amplification was performed using plasmids pEASY-GAL1p-MtCYP108-PRM9t and pEASY-GAL1p-MtCYP150-PRM9t as templates and primers YJL064W-50-GAL1p-F / YJL064W-50-PRM9t-R to obtain MtCYP108 and MtCYP150 functional gene expression cassettes (fragments M12 and M13), respectively, and the PCR products were recovered.
[0194] Amplification system (50 μl) contains: TAKARA HS DNA polymerase 5×PS Buffer 10μl, dNTPMix 4μl, primers 1.5μl each, DNA template 0.5μl, HS polymerase (2.5 U / μl) 0.5 μl, ddH2O (to make up the volume).
[0195] Amplification conditions included:
[0196] Pre-denaturation at 98°C for 3 minutes;
[0197] Denaturation at 98°C for 10 seconds, annealing at 58°C for 15 seconds, and extension at 72°C for 3 minutes (30 cycles); and
[0198] Extend at 72°C for 10 minutes.
[0199] YJL064W-50-GAL1p-F:
[0200] TCGGAGCCGTATCGTTCACCACATAGGCGGAGTAAACTTCATTAGGGGGCTTATA
[0201] TTGAATTTTCAAAAATTCTTAC (SEQ ID NO:92).
[0202] YJL064W-50-PRM9t-R
[0203] AAACAGAAGAAACAAGAGAGAATAGCGTCAGGATAGCTCGCTCGATGTGAATT
[0204] TTCAACATCGTATTTTCCGAAG (SEQ ID NO:93).
[0205] Strains CAOL01 and CHOL02 were activated in SD-Trp liquid culture medium, respectively, and competent cells were prepared by the lithium acetate method. 2 μl of plasmid YJL064W-gRNA (see Li R, Wang K, Wang D, et al. Production of plantvolatile terpenoids (rose oil) by yeast cell factories [J]. Green Chemistry, 2021, 23 (14)) and 2 μl of M12 and M13 fragments were added to the yeast competent cells, respectively. The transformants were cultured in SD-Trp-Ura solid selection medium at 30°C in an incubator for 48 hours and then streaked. The primers MtCYP108-YZ-F: ACCTGAAGGAAAAACTGATCCTTGA (SEQ ID NO: 94) and YJL064W-OUTR: CCTATGTCATGGTTCCCAGACC (SEQ ID NO: 95) and the primers MtCYP150-YZ-F: AGCTGGTGTTCAAACTTTCAGCA (SEQ ID NO: 96) and YJL064W-OUT-R: CCTATGTCATGGTTCCCAGACC (SEQ ID NO: 97) were used for PCR verification (PCR system and conditions were as described above). The obtained strains were named CAOL-Mt108, CAOL-Mt150, CHOL-Mt108, and CHOL-Mt150.
[0206] For information related to the engineered strains prepared above, see Table 9.
[0207] Table 9. Engineering strain information
[0208]
[0209] Case study 3: Identification of the functions of strains CAOL-Mt108, CAOL-Mt150, CHOL-Mt108, and CHOL-Mt150
[0210] 3.1、Cultivation of engineered bacteria
[0211] The strains CAOL-Mt108, CAOL-Mt150, CHOL-Mt108, CHOL-Mt150, CAOL01 and CHOL02 were activated on SD-Trp-Ura solid selection medium, and seed solution was prepared in SD-TrpUra liquid selection medium (30°C, 250rpm, 16h), and 1% of the seed solution was inoculated in a 100ml Erlenmeyer flask containing 15ml of SD-Trp-Ura liquid selection medium with 2% glucose as carbon source, and cultured at 30°C, 250rpm for 48h. The culture was placed in a sterile 50ml centrifuge tube, centrifuged at 6,000rpm for 5min, and the supernatant was removed, 15ml of SD-Trp-Ura liquid selection medium containing 1% galactose and 2% ethanol was added, and the culture was transferred to a new 100ml Erlenmeyer flask and cultured for 96h.
[0212] 3.2 Product extraction and analysis
[0213] After the culture, take 2 ml of bacterial solution in a crushing tube, centrifuge to remove the supernatant, add 1 ml of methanol: acetone (1:1) and appropriate glass beads, use a oscillating crusher to oscillate for 10 minutes, and ultrasonicate for 30 minutes. After ultrasonication, centrifuge at 13,000 rpm for 1 minute, take the supernatant and filter it with a Jinlong organic nylon membrane (0.22μm), and detect the presence of pregnenolone by GC-MS (Thermo scientific Trace1300 GC–Orbitrap Exploris GC 240GC / MS).
[0214] GC-MS determination conditions: injection port temperature 250℃, injection volume 1μL, no splitting, solvent delay 3min; chromatographic column: DB-35ms (30m*0.25mM); chromatographic conditions: 100℃, 1min, 20℃ / min to 320℃ for 15min; MS conditions: FullScan: 40-600amu. Pregnenolone standard was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (Cat. No.: P129412); cholesterol standard was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Cat. No.: S23165); campesterol standard was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Cat. No.: S31679). The experiment was repeated three times.
[0215] like Figure 1-Figure 2 As shown, the fermentation products of CAOL-Mt108, CAOL-Mt150, CHOL-Mt108, and CHOL-Mt150 strains contained pregnenolone, while the fermentation products of CAOL and CHOL02 strains did not, indicating that the new cytochrome P450 (MtCYP108, MtCYP150) isolated by the inventors has the activity of catalyzing the conversion of cholesterol and campesterol into pregnenolone.
[0216] sequence
[0217] SEQ ID NO:1 GAL1p-tHMG1-PRM9t expression cassette
[0218]
[0219] SEQ ID NO:2 GAL7p-cHMG2-SPG5t expression cassette
[0220]
[0221] SEQ ID NO:3 GAL10p-HMGR-CWP2t expression cassette
[0222]
[0223] SEQ ID NO:4 PGK1p-tHMG1-ADH1t expression cassette
[0224]
[0225] SEQ ID NO:5 TDH3p-INO2-TPI1t expression cassette
[0226]
[0227] SEQ ID NO:6 TEF1p-PDI1-CYC1t expression cassette
[0228]
[0229] SEQ ID NO:7 GAL1p-GgDHCR24-PRM9t expression cassette
[0230]
[0231] SEQ ID NO:8 GAL7p-VvCPR-SPG5t expression cassette
[0232]
[0233] SEQ ID NO:9 GAL10p-StDWF5-CWP2t expression cassette
[0234]
[0235] SEQ ID NO:10 GAL1p-VvCPR-PRM9t expression cassette
[0236]
[0237] SEQ ID NO:11 GAL1p-MtCYP108-PRM9t expression cassette
[0238]
[0239] SEQ ID NO:12 GAL1p-MtCYP150-PRM9t expression cassette
[0240]
[0241] SEQ ID NO:13 Amino acid sequence of MtCYP108
[0242] MAFAIVLGTFLVILISRWVYRWRNPRCNGVLPPGSMGLPIIGESIDYFTPYLKDDVPLFIRKRVSKYGPLFRTSIVGQPVVVSTDPEVNYYVFQQEGNIFQCWYSESVNRIIGKQSMAVQQGVVHKYLKNLILSLVGPENLKEKLILEMDQNTQQHLHSWANLGNLDAKEATAEMVFTLAARKILNYDDKKASQELRDCYKAFLDGFISFPLYIPGTAFYACIQGRRKALKVIKSIFNERRASMEKKAKNDFVDAVLEEVDSKGSFLNEEIALDLVFLLLFASHETTSTAMTLAMKYLSQHPAILAELVREHEAILNNRETEAGSSSAITWKEYKSMTFTHMIINETVRLANIAPGIFRKVMKEVEIKGYTIPEGWTLMVCPSSVHMNVDKYEDPLAFNPWRWEGQELHSASKNFMAFGGGMRLCVGADFAKLQMAIFLHYLVTKYRWVITGGGNTIRKPGLLFPDGFHVHISNKADA
[0243] SEQ ID NO:14 Amino acid sequence of MtCYP150
[0244] MFAIFLTTFLFIILSRWIYRWRNPTCNGILPPGSMGLPIIGESLAYFTPYSKDDIPLFIRKRVQKYGPLFRTSLVGQPVIVSTDNEVNYYIFQQEGNLFQCWYSESVLKVLGEQSMAVQAGAFHKYLRNLVLSLVGPENLKEKLMYEMDQNTKQHLDSWGTIGNLDARDATAELVFKLSARKILNYDEKKAGKKLRDCYKAFLDGFISFPLYIPGTAFYACIQGRKKALKVIKEIFNQRRRSGEKHNDFVDYVLEEIDNKESFINEGIAQDLVFLLLFASHETTSTAMTMAMKFLTESPAVLAELVREHEAIIKSRENPDSGFTWKEYKAVNFTHMVINETVRIANIAPGIFRKVMKEVEIKGYTIPAGWTVMVCPSTVHMNPDKYEDPLSFDPWRWEGQELHSASKNFMAFGGGMRLCAGADFAKVQLAIFLHHLVTKYRWTITHGGDTVRKPGLLFPNGMHVQISTLKAK
[0245] SEQ ID NO:98 GAL1-7-10 gene knockout fragment
[0246]
Claims
1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or 14.
2. An isolated polynucleotide encoding the polypeptide of claim 1. A vector comprising the polynucleotide of claim 2.
4. A recombinant host cell, such as a eukaryotic cell, preferably a yeast cell, such as a Saccharomyces cerevisiae cell, comprising the polynucleotide of claim 2 or the vector of claim 3.
5. The host cell of claim 4, wherein the polynucleotide is integrated into the genome of the host cell.
6. The host cell of claim 4 or 5, further comprising a polynucleotide encoding a protein involved in cholesterol and / or campesterol biosynthesis.
7. The host cell of any one of claims 4 to 6, wherein the cholesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, protein disulfide isomerase, INO2 protein; cytochrome P450 reductase, 7-dehydrocholesterol reductase and sterol 24-reductase; and / or wherein the campesterol biosynthesis-related protein is selected from 3-hydroxy-3-methylglutaryl-CoA reductase, cytochrome P450 reductase, 7-dehydrocholesterol reductase.
8. The host cell of any one of claims 4-7, wherein the host cell lacks a galactokinase gene.
9. The host cell of claim 8, wherein the galactokinase gene is one or more of the GAL1, GAL7 and GAL10 genes.
10. A polypeptide-membrane complex comprising the polypeptide of claim 1 and a membrane comprising a lipid bilayer.
11. A method for preparing pregnenolone, comprising contacting the host cell of claim 4 or 5 or the complex of claim 10 with cholesterol and / or campesterol.
12. A method for preparing pregnenolone, comprising culturing the host cell according to any one of claims 6 to 9 under conditions suitable for its growth.
Citation Information
Cited By
Compound salvia miltiorrhiza biomimetic synthetic engineering bacterium and application thereof
CN119931857A
A compound Danshen bionic synthesis engineering bacterium and its application
CN119931857B
Plant source dehydrogenase and application thereof
CN122278988A
Enzyme composition containing P450 enzyme and application of enzyme composition in steroid production
CN122445590A
